✦ LIBER ✦

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women

✍ Scribed by I Vergote

Book ID: 117659078
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 68 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)00287-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fulvestrant: an effective second-line tr

Fulvestrant: an effective second-line treatment for postmenopausal women with advanced breast cancer

✍ D Dodwell; I Vergote 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 313 KB

Randomised study of anastrozole versus t

Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women

✍ I. Vergote; J. Bonneterre; B. Thürlimann; J. Robertson; M. Krzakowski; L. Mauria 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Cost-effectiveness of anastrozole versus

Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer

✍ W.Robert Simons; David Jones; Aman Buzdar 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Fulvestrant (Faslodex™) versus anastrozo

Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

✍ L. Mauriac; J.E. Pippen; J. Quaresma Albano; S.Z. Gertler; C.K. Osborne 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 196 KB

Efficacy of tamoxifen following anastroz

Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women

✍ B. Thürlimann; J.F.R. Robertson; J.M. Nabholtz; A. Buzdar; J. Bonneterre 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 247 KB

Fulvestrant versus anastrozole for the t

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women : A prospective combined analysis of two multicenter trials

✍ John F. R. Robertson; C. Kent Osborne; Anthony Howell; Stephen E. Jones; Louis M 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract ## BACKGROUND Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down‐regulates the ER and has no known agonist effects. The authors report the prospectively planned combined analysis of data from 2 Phase III trials comparing fulvestrant 250 mg monthly (_